P2X Receptor Chimeras Highlight Roles of the Amino Terminus to Partial Agonist Efficacy, the Carboxyl Terminus to Recovery from Desensitization, and Independent Regulation of Channel Transitions

P2X receptor subtypes can be distinguished by their sensitivity to ATP analogues and selective antagonists. We have used chimeras between human P2X1 and P2X2 receptors to address the contribution of the extracellular ligand binding loop, transmembrane segments (TM1 and TM2), and intracellular amino...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of biological chemistry 2013-07, Vol.288 (29), p.21412-21421
Hauptverfasser: Allsopp, Rebecca C., Farmer, Louise K., Fryatt, Alistair G., Evans, Richard J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 21421
container_issue 29
container_start_page 21412
container_title The Journal of biological chemistry
container_volume 288
creator Allsopp, Rebecca C.
Farmer, Louise K.
Fryatt, Alistair G.
Evans, Richard J.
description P2X receptor subtypes can be distinguished by their sensitivity to ATP analogues and selective antagonists. We have used chimeras between human P2X1 and P2X2 receptors to address the contribution of the extracellular ligand binding loop, transmembrane segments (TM1 and TM2), and intracellular amino and carboxyl termini to the action of partial agonists (higher potency and efficacy of BzATP and Ap5A at P2X1 receptors) and antagonists. Sensitivity to the antagonists NF449, suramin, and PPADS was conferred by the nature of the extracellular loop (e.g. nanomolar for NF449 at P2X1 and P2X2-1EXT and micromolar at P2X2 and P2X1-2EXT). In contrast, the effectiveness of partial agonists was similar to P2X1 levels for both of the loop transfers, suggesting that interactions with the rest of the receptor played an important role. Swapping TM2 had reciprocal effects on partial agonist efficacy. However, TM1 swaps increased partial agonist efficacy at both chimeras, and this was similar for swaps of both TM1 and 2. Changing the amino terminus had no effect on agonist potency but increased partial agonist efficacy at P2X2-1N and decreased it at P2X1-2N chimeras, demonstrating that potency and efficacy can be independently regulated. Chimeras and point mutations also identified residues in the carboxyl terminus that regulated recovery from channel desensitization. These results show that interactions among the intracellular, transmembrane, and extracellular portions of the receptor regulate channel properties and suggest that transitions to channel opening, the behavior of the open channel, and recovery from the desensitized state can be controlled independently. Background: P2X receptor subtypes show differences in pharmacology. Results: Chimeric P2X receptors exhibit modified partial agonist action and recovery from desensitization. Conclusion: Interactions among the extracellular, transmembrane, and intracellular regions regulate channel properties. Significance: Agonist binding and transitions to channel opening (efficacy), behavior of the open channel, as well as recovery from desensitization can be controlled independently.
doi_str_mv 10.1074/jbc.M113.464651
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3774408</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0021925820455735</els_id><sourcerecordid>23740251</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-2fa4cdba11a7a38c5b3738c6c0460cf1402a69e83f7459a4ab1f540730cd50183</originalsourceid><addsrcrecordid>eNp1UU1vEzEQXSEQDYUzN-Qf0E3ttffrghSFQisVUVVF6s2a9Y6zrnbtyHYiws_rL6uTQEUPWLLfYd57M-OXZR8ZnTNai_OHTs2_M8bnohJVyV5lM0YbnvOS3b_OZpQWLG-LsjnJ3oXwQNMRLXubnRS8FrQo2Sx7vCnuyS0qXEfnyXIwE3oI5NKshjHdSG7diIE4TeKAZDEZ68gd-oSbQKIjN-CjgZEsVs6aEMmF1kaB2p0d-Evwnfu1G19IUje3Rb8j2ruJfMGANphofkM0zp4RsD25sj2uMT02DYCrzXio7adYDmAtJkMPB5Wz4X32RsMY8MMfPM1-fr24W17m1z--XS0X17kSgse80CBU3wFjUANvVNnxOkGlqKio0ix9CFQtNlzXomxBQMd0KWjNqepLyhp-mn0--q433YS9SsN5GOXamwn8Tjow8mXFmkGu3FbyuhaC7g3OjwbKuxA86mcto3Ifp0xxyn2c8hhnUnz6t-Uz_29-idAeCZgW3xr0MiiDVmFvPKooe2f-a_4EMs-0OA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>P2X Receptor Chimeras Highlight Roles of the Amino Terminus to Partial Agonist Efficacy, the Carboxyl Terminus to Recovery from Desensitization, and Independent Regulation of Channel Transitions</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Allsopp, Rebecca C. ; Farmer, Louise K. ; Fryatt, Alistair G. ; Evans, Richard J.</creator><creatorcontrib>Allsopp, Rebecca C. ; Farmer, Louise K. ; Fryatt, Alistair G. ; Evans, Richard J.</creatorcontrib><description>P2X receptor subtypes can be distinguished by their sensitivity to ATP analogues and selective antagonists. We have used chimeras between human P2X1 and P2X2 receptors to address the contribution of the extracellular ligand binding loop, transmembrane segments (TM1 and TM2), and intracellular amino and carboxyl termini to the action of partial agonists (higher potency and efficacy of BzATP and Ap5A at P2X1 receptors) and antagonists. Sensitivity to the antagonists NF449, suramin, and PPADS was conferred by the nature of the extracellular loop (e.g. nanomolar for NF449 at P2X1 and P2X2-1EXT and micromolar at P2X2 and P2X1-2EXT). In contrast, the effectiveness of partial agonists was similar to P2X1 levels for both of the loop transfers, suggesting that interactions with the rest of the receptor played an important role. Swapping TM2 had reciprocal effects on partial agonist efficacy. However, TM1 swaps increased partial agonist efficacy at both chimeras, and this was similar for swaps of both TM1 and 2. Changing the amino terminus had no effect on agonist potency but increased partial agonist efficacy at P2X2-1N and decreased it at P2X1-2N chimeras, demonstrating that potency and efficacy can be independently regulated. Chimeras and point mutations also identified residues in the carboxyl terminus that regulated recovery from channel desensitization. These results show that interactions among the intracellular, transmembrane, and extracellular portions of the receptor regulate channel properties and suggest that transitions to channel opening, the behavior of the open channel, and recovery from the desensitized state can be controlled independently. Background: P2X receptor subtypes show differences in pharmacology. Results: Chimeric P2X receptors exhibit modified partial agonist action and recovery from desensitization. Conclusion: Interactions among the extracellular, transmembrane, and intracellular regions regulate channel properties. Significance: Agonist binding and transitions to channel opening (efficacy), behavior of the open channel, as well as recovery from desensitization can be controlled independently.</description><identifier>ISSN: 0021-9258</identifier><identifier>EISSN: 1083-351X</identifier><identifier>DOI: 10.1074/jbc.M113.464651</identifier><identifier>PMID: 23740251</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adenosine Triphosphate - pharmacology ; Animals ; ATP ; Electrophysiology ; Extracellular Space - chemistry ; Humans ; Intracellular Space - chemistry ; Ion Channel Gating - drug effects ; Ion Channels ; Models, Biological ; Mutagenesis ; Pharmacology ; Protein Structure, Secondary ; Protein Structure, Tertiary ; Purinergic P2X Receptor Agonists - pharmacology ; Purinergic P2X Receptor Antagonists ; Pyridoxal Phosphate - pharmacology ; Receptors, Purinergic P2X1 - chemistry ; Receptors, Purinergic P2X1 - metabolism ; Receptors, Purinergic P2X2 - chemistry ; Receptors, Purinergic P2X2 - metabolism ; Recombinant Proteins - chemistry ; Recombinant Proteins - metabolism ; Signal Transduction ; Structure-Activity Relationship ; Time Factors ; Xenopus laevis</subject><ispartof>The Journal of biological chemistry, 2013-07, Vol.288 (29), p.21412-21421</ispartof><rights>2013 © 2013 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology.</rights><rights>2013 by The American Society for Biochemistry and Molecular Biology, Inc. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-2fa4cdba11a7a38c5b3738c6c0460cf1402a69e83f7459a4ab1f540730cd50183</citedby><cites>FETCH-LOGICAL-c443t-2fa4cdba11a7a38c5b3738c6c0460cf1402a69e83f7459a4ab1f540730cd50183</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3774408/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3774408/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23740251$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Allsopp, Rebecca C.</creatorcontrib><creatorcontrib>Farmer, Louise K.</creatorcontrib><creatorcontrib>Fryatt, Alistair G.</creatorcontrib><creatorcontrib>Evans, Richard J.</creatorcontrib><title>P2X Receptor Chimeras Highlight Roles of the Amino Terminus to Partial Agonist Efficacy, the Carboxyl Terminus to Recovery from Desensitization, and Independent Regulation of Channel Transitions</title><title>The Journal of biological chemistry</title><addtitle>J Biol Chem</addtitle><description>P2X receptor subtypes can be distinguished by their sensitivity to ATP analogues and selective antagonists. We have used chimeras between human P2X1 and P2X2 receptors to address the contribution of the extracellular ligand binding loop, transmembrane segments (TM1 and TM2), and intracellular amino and carboxyl termini to the action of partial agonists (higher potency and efficacy of BzATP and Ap5A at P2X1 receptors) and antagonists. Sensitivity to the antagonists NF449, suramin, and PPADS was conferred by the nature of the extracellular loop (e.g. nanomolar for NF449 at P2X1 and P2X2-1EXT and micromolar at P2X2 and P2X1-2EXT). In contrast, the effectiveness of partial agonists was similar to P2X1 levels for both of the loop transfers, suggesting that interactions with the rest of the receptor played an important role. Swapping TM2 had reciprocal effects on partial agonist efficacy. However, TM1 swaps increased partial agonist efficacy at both chimeras, and this was similar for swaps of both TM1 and 2. Changing the amino terminus had no effect on agonist potency but increased partial agonist efficacy at P2X2-1N and decreased it at P2X1-2N chimeras, demonstrating that potency and efficacy can be independently regulated. Chimeras and point mutations also identified residues in the carboxyl terminus that regulated recovery from channel desensitization. These results show that interactions among the intracellular, transmembrane, and extracellular portions of the receptor regulate channel properties and suggest that transitions to channel opening, the behavior of the open channel, and recovery from the desensitized state can be controlled independently. Background: P2X receptor subtypes show differences in pharmacology. Results: Chimeric P2X receptors exhibit modified partial agonist action and recovery from desensitization. Conclusion: Interactions among the extracellular, transmembrane, and intracellular regions regulate channel properties. Significance: Agonist binding and transitions to channel opening (efficacy), behavior of the open channel, as well as recovery from desensitization can be controlled independently.</description><subject>Adenosine Triphosphate - pharmacology</subject><subject>Animals</subject><subject>ATP</subject><subject>Electrophysiology</subject><subject>Extracellular Space - chemistry</subject><subject>Humans</subject><subject>Intracellular Space - chemistry</subject><subject>Ion Channel Gating - drug effects</subject><subject>Ion Channels</subject><subject>Models, Biological</subject><subject>Mutagenesis</subject><subject>Pharmacology</subject><subject>Protein Structure, Secondary</subject><subject>Protein Structure, Tertiary</subject><subject>Purinergic P2X Receptor Agonists - pharmacology</subject><subject>Purinergic P2X Receptor Antagonists</subject><subject>Pyridoxal Phosphate - pharmacology</subject><subject>Receptors, Purinergic P2X1 - chemistry</subject><subject>Receptors, Purinergic P2X1 - metabolism</subject><subject>Receptors, Purinergic P2X2 - chemistry</subject><subject>Receptors, Purinergic P2X2 - metabolism</subject><subject>Recombinant Proteins - chemistry</subject><subject>Recombinant Proteins - metabolism</subject><subject>Signal Transduction</subject><subject>Structure-Activity Relationship</subject><subject>Time Factors</subject><subject>Xenopus laevis</subject><issn>0021-9258</issn><issn>1083-351X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1UU1vEzEQXSEQDYUzN-Qf0E3ttffrghSFQisVUVVF6s2a9Y6zrnbtyHYiws_rL6uTQEUPWLLfYd57M-OXZR8ZnTNai_OHTs2_M8bnohJVyV5lM0YbnvOS3b_OZpQWLG-LsjnJ3oXwQNMRLXubnRS8FrQo2Sx7vCnuyS0qXEfnyXIwE3oI5NKshjHdSG7diIE4TeKAZDEZ68gd-oSbQKIjN-CjgZEsVs6aEMmF1kaB2p0d-Evwnfu1G19IUje3Rb8j2ruJfMGANphofkM0zp4RsD25sj2uMT02DYCrzXio7adYDmAtJkMPB5Wz4X32RsMY8MMfPM1-fr24W17m1z--XS0X17kSgse80CBU3wFjUANvVNnxOkGlqKio0ix9CFQtNlzXomxBQMd0KWjNqepLyhp-mn0--q433YS9SsN5GOXamwn8Tjow8mXFmkGu3FbyuhaC7g3OjwbKuxA86mcto3Ifp0xxyn2c8hhnUnz6t-Uz_29-idAeCZgW3xr0MiiDVmFvPKooe2f-a_4EMs-0OA</recordid><startdate>20130719</startdate><enddate>20130719</enddate><creator>Allsopp, Rebecca C.</creator><creator>Farmer, Louise K.</creator><creator>Fryatt, Alistair G.</creator><creator>Evans, Richard J.</creator><general>Elsevier Inc</general><general>American Society for Biochemistry and Molecular Biology</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20130719</creationdate><title>P2X Receptor Chimeras Highlight Roles of the Amino Terminus to Partial Agonist Efficacy, the Carboxyl Terminus to Recovery from Desensitization, and Independent Regulation of Channel Transitions</title><author>Allsopp, Rebecca C. ; Farmer, Louise K. ; Fryatt, Alistair G. ; Evans, Richard J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-2fa4cdba11a7a38c5b3738c6c0460cf1402a69e83f7459a4ab1f540730cd50183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adenosine Triphosphate - pharmacology</topic><topic>Animals</topic><topic>ATP</topic><topic>Electrophysiology</topic><topic>Extracellular Space - chemistry</topic><topic>Humans</topic><topic>Intracellular Space - chemistry</topic><topic>Ion Channel Gating - drug effects</topic><topic>Ion Channels</topic><topic>Models, Biological</topic><topic>Mutagenesis</topic><topic>Pharmacology</topic><topic>Protein Structure, Secondary</topic><topic>Protein Structure, Tertiary</topic><topic>Purinergic P2X Receptor Agonists - pharmacology</topic><topic>Purinergic P2X Receptor Antagonists</topic><topic>Pyridoxal Phosphate - pharmacology</topic><topic>Receptors, Purinergic P2X1 - chemistry</topic><topic>Receptors, Purinergic P2X1 - metabolism</topic><topic>Receptors, Purinergic P2X2 - chemistry</topic><topic>Receptors, Purinergic P2X2 - metabolism</topic><topic>Recombinant Proteins - chemistry</topic><topic>Recombinant Proteins - metabolism</topic><topic>Signal Transduction</topic><topic>Structure-Activity Relationship</topic><topic>Time Factors</topic><topic>Xenopus laevis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Allsopp, Rebecca C.</creatorcontrib><creatorcontrib>Farmer, Louise K.</creatorcontrib><creatorcontrib>Fryatt, Alistair G.</creatorcontrib><creatorcontrib>Evans, Richard J.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of biological chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Allsopp, Rebecca C.</au><au>Farmer, Louise K.</au><au>Fryatt, Alistair G.</au><au>Evans, Richard J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P2X Receptor Chimeras Highlight Roles of the Amino Terminus to Partial Agonist Efficacy, the Carboxyl Terminus to Recovery from Desensitization, and Independent Regulation of Channel Transitions</atitle><jtitle>The Journal of biological chemistry</jtitle><addtitle>J Biol Chem</addtitle><date>2013-07-19</date><risdate>2013</risdate><volume>288</volume><issue>29</issue><spage>21412</spage><epage>21421</epage><pages>21412-21421</pages><issn>0021-9258</issn><eissn>1083-351X</eissn><abstract>P2X receptor subtypes can be distinguished by their sensitivity to ATP analogues and selective antagonists. We have used chimeras between human P2X1 and P2X2 receptors to address the contribution of the extracellular ligand binding loop, transmembrane segments (TM1 and TM2), and intracellular amino and carboxyl termini to the action of partial agonists (higher potency and efficacy of BzATP and Ap5A at P2X1 receptors) and antagonists. Sensitivity to the antagonists NF449, suramin, and PPADS was conferred by the nature of the extracellular loop (e.g. nanomolar for NF449 at P2X1 and P2X2-1EXT and micromolar at P2X2 and P2X1-2EXT). In contrast, the effectiveness of partial agonists was similar to P2X1 levels for both of the loop transfers, suggesting that interactions with the rest of the receptor played an important role. Swapping TM2 had reciprocal effects on partial agonist efficacy. However, TM1 swaps increased partial agonist efficacy at both chimeras, and this was similar for swaps of both TM1 and 2. Changing the amino terminus had no effect on agonist potency but increased partial agonist efficacy at P2X2-1N and decreased it at P2X1-2N chimeras, demonstrating that potency and efficacy can be independently regulated. Chimeras and point mutations also identified residues in the carboxyl terminus that regulated recovery from channel desensitization. These results show that interactions among the intracellular, transmembrane, and extracellular portions of the receptor regulate channel properties and suggest that transitions to channel opening, the behavior of the open channel, and recovery from the desensitized state can be controlled independently. Background: P2X receptor subtypes show differences in pharmacology. Results: Chimeric P2X receptors exhibit modified partial agonist action and recovery from desensitization. Conclusion: Interactions among the extracellular, transmembrane, and intracellular regions regulate channel properties. Significance: Agonist binding and transitions to channel opening (efficacy), behavior of the open channel, as well as recovery from desensitization can be controlled independently.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>23740251</pmid><doi>10.1074/jbc.M113.464651</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-9258
ispartof The Journal of biological chemistry, 2013-07, Vol.288 (29), p.21412-21421
issn 0021-9258
1083-351X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3774408
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection
subjects Adenosine Triphosphate - pharmacology
Animals
ATP
Electrophysiology
Extracellular Space - chemistry
Humans
Intracellular Space - chemistry
Ion Channel Gating - drug effects
Ion Channels
Models, Biological
Mutagenesis
Pharmacology
Protein Structure, Secondary
Protein Structure, Tertiary
Purinergic P2X Receptor Agonists - pharmacology
Purinergic P2X Receptor Antagonists
Pyridoxal Phosphate - pharmacology
Receptors, Purinergic P2X1 - chemistry
Receptors, Purinergic P2X1 - metabolism
Receptors, Purinergic P2X2 - chemistry
Receptors, Purinergic P2X2 - metabolism
Recombinant Proteins - chemistry
Recombinant Proteins - metabolism
Signal Transduction
Structure-Activity Relationship
Time Factors
Xenopus laevis
title P2X Receptor Chimeras Highlight Roles of the Amino Terminus to Partial Agonist Efficacy, the Carboxyl Terminus to Recovery from Desensitization, and Independent Regulation of Channel Transitions
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T09%3A13%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P2X%20Receptor%20Chimeras%20Highlight%20Roles%20of%20the%20Amino%20Terminus%20to%20Partial%20Agonist%20Efficacy,%20the%20Carboxyl%20Terminus%20to%20Recovery%20from%20Desensitization,%20and%20Independent%20Regulation%20of%20Channel%20Transitions&rft.jtitle=The%20Journal%20of%20biological%20chemistry&rft.au=Allsopp,%20Rebecca%20C.&rft.date=2013-07-19&rft.volume=288&rft.issue=29&rft.spage=21412&rft.epage=21421&rft.pages=21412-21421&rft.issn=0021-9258&rft.eissn=1083-351X&rft_id=info:doi/10.1074/jbc.M113.464651&rft_dat=%3Cpubmed_cross%3E23740251%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/23740251&rft_els_id=S0021925820455735&rfr_iscdi=true